Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

Peter Gratton, Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, economics, and public policy. Peter began covering markets at Multex (Reuters) and has ...

Starbucks is revamping its loyalty program and one of the new twists is that you can keep your rewards stars from expiring. The revamped program will launch on March 10 with three free membership ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

CNBC ranks the 75 most valuable college athletic programs. The programs are worth a combined $51.22 billion, 13% more than the top 75 in last year's rankings. Earlier this month the University of Utah ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...